EQS-News

Medios achieves double-digit growth in 2023 – Positive outlook for 2024

EQS-News: Medios AG / Key word(s): Annual Results Medios achieves double-digit growth in 2023 – Positive outlook for 2024 27.03.2024 / 07:54 CET/CEST The issuer is solely responsible for the content of this announcement. Press release

Medios achieves double-digit growth in 2023 – Positive outlook for 2024

Berlin, March 27, 2024 - Medios AG ("Medios"), the leading provider of specialty pharma solutions in Germany, once again grew strongly in the 2023 financial year. From January to December 2023, consolidated revenue increased by 10.8% to around €1.8 billion (previous year: €1.6 billion), thus meeting the latest forecast. EBITDA pre¹ rose by 10.3% to around €60.5 million (previous year: €54.9 million), exceeding the most recent forecast of around €60 million. The EBITDA pre¹ margin thus remained at the previous year's level of 3.4%.

Highlights:

• Increase in consolidated revenue in 2023 by approx. 11% to around €1.8 billion; EBITDA pre¹ 2023 increases by 10.3% to €60.5 million with stable EBITDA pre¹ margin of 3.4%.
• Closing of the acquisition of the Dutch market leader for pharmaceutical compounding services Ceban expected in the second quarter of 2024.
• Guidance 2024: Significant increase in revenue and margin: revenue between €1.9 billion and €2.1 billion; EBITDA pre¹ between €82 million and €91 million with a margin of around 4.3%.
• Medium-term outlook for the 2025 financial year: revenue of around €2.15 billion and EBITDA pre¹ of around €110 million, which corresponds to a margin of around 5.1%.

Matthias Gärtner, Chief Executive Officer (CEO) of Medios AG: "Despite challenging conditions in the 2023 financial year, we continued to consistently implement our growth strategy and once again achieved our ambitious forecast in the 2023 financial year. With the recent acquisition of the Dutch compounding manufacturer and market leader Ceban, we are implementing a significant strategic growth measure. This is just the beginning: We want to expand into other European countries and enter the market for personalized medicine."